CONGRATULATIONS! BIOTECH AKRO BUYOUT BY NVO BECOMES 213TH ARORA PORTFOLIO BUYOUT
By Nigam Arora NVO, the maker of weight loss drug Wegovy, is buying AKRO. The deal is for $60 per share. The deal consists of $54 per share in cash to be paid on closing and $6 per share in cash upon U.S. regulatory approval of efruxifermin drug cirrhosis. What To
October 9, 2025